CBG Producer Willow Biosciences Reports Record Q2 Revenue, Enters Major Pharma Deal Slated To Be Key Driver Of Growth
Willow Biosciences Inc. (TSX: WLLW) (OTCQB:CANSF) reported its financial and operating results on Monday for the three months ended June 30, 2024, reporting significantly higher revenue and reduced costs.
“The second quarter was marked by significant pipeline and revenue growth with the addition of the Laurus Labs strategic partnership that includes seven high-value APIs,” Dr. Chris Savile, Willow’s president and CEO said. “In addition, the Company further strengthened its balance sheet by launching a private placement in June, which closed after the end of the quarter, and continued on its path to further increase efficiency and reduce costs.”
Read Also: CBG Producer Willow Biosciences Announces Record 43% Revenue Increase And Strategic Moves Ahead
Willow is a precision fermentation company that uses advanced science and technology to produce natural ingredients for the health and wellness, food and beverage and …